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Abstract We investigated the previously-demonstrated asso-
ciation of seven genome-wide association studies (GWAS)
single nucleotide polymorphisms (SNPs), including
rs2072590 (HOXD-AS1), rs2665390 (TIPARP), rs10088218
and rs10098821 (8q24), rs3814113 (9p22), rs9303542
(SKAP1) and rs2363956 (ANKLE1), as risk factors of epithe-
lial ovarian tumors (EOTs). These SNPs were genotyped in
two hundred seventy three patients with EOTs and four hun-
dred sixty four unrelated healthy females from the Polish
population. We observed the lowest p values of the trend test
for the 9p22 rs3814113 and 8q24 rs10098821 SNPs in pa-
tients with all subtypes of ovarian cancer (ptrend=0.010 and
ptrend=0.014, respectively). There were also significant p
values for the trend of the 9p22 rs3814113 and the 8q24
rs10098821 SNPs for serous histological subtypes of ovarian
cancer (ptrend=0.006, ptrend=0.033, respectively). Moreover,
stratification of the patients based on their histological type of
cancer demonstrated, in the dominant hereditary model, a
significant association of the 9p22 rs3814113 SNP with se-
rous ovarian carcinoma OR=0.532 (95 % CI=0.342 - 0.827,
p=0.005, pcorr=0.035). Despite the relatively small sample
size of cases and controls, our studies confirmed some of the
previously-demonstrated GWAS SNPs as genetic risk factors
for EOTs.
Keywords Ovarian cancer . Single nucleotide
polymorphisms . Genome-wide association studies
Introduction
Epithelial ovarian tumors (EOTs) are currently the leading
cause of mortality among gynecological carcinomas in Europe
and the United States, causing approximately 4 % of deaths
from malignancies in women [1, 2]. This high mortality of
EOTs is due to late diagnosis, which results from the nonspe-
cific symptoms in the beginning stages of EOTs and a lack of
robust serum biomarkers for EOTs screening [3]. There are
recognized factors that can either reduce or increase the risk of
EOTs development [4–16]. Multiparity, breastfeeding, tubal
ligation and oral contraceptive use all display a protective role
in ovarian cancer development [4–8]. The risk factors for EOTs
include early age of menarche, late age of natural menopause,
hormone replacement therapy (HRT), nulliparity , infertility,
obesity and some lifestyle factors [8–13]. Other factors contrib-
uting to EOTs development include endometriosis, pelvic in-
flammatory disease, environmental toxins and geographical
location, the latter related to sun exposure and vitamin D
production [13–16]. However, one of the greatest risk factors
for EOTs are inherited genetic components, including a family
history of ovarian tumors, especially in first-degree relatives,
and a personal history of breast tumors [17–21]. The firmly
established genetic background of EOTs encompasses certain
high-penetrance genes: BRCA1 (3–6 %), BRCA2 (1–3 %), and
HNPCC DNA mismatch repair genes (1–2 %) [19–21]. How-
ever, the genetic variants of high-penetrance genes are involved
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in less than 40 % of the hereditary susceptibility to EOTs
[19–21]. This suggests that the development of EOTs may
involve low-penetrance risk genes that may account for a
variable heritability pattern. in a multigenic EOTs model
[19–21]. The early events and pathogenesis of ovarian tumor-
igenesis remain elusive [21]. Three recently conducted
genome-wide association studies (GWAS) in patients with
EOTs indicated seven risk alleles amounting genome-wide
significance, at loci 9p22, 8q24, 2q31, 19p13, 3q25 and
17q21 [22–24]. We replicated the distribution of the top seven
ovarian cancer susceptibility GWAS SNPs including
rs2072590 on 2q31 (HOXD-AS1), rs2665390 on 3q25
(TIPARP), rs10088218 and rs10098821 on 8q24, rs3814113
on 9p22, rs9303542 on 17q21 (SKAP1) and rs2363956 on
19p13 (ANKLE1), in patients with ovarian cancer and controls
from a sample of the Polish population.
Material and Methods
Patients and Controls
The patient group consisted of 273 women with histologically
diagnosed ovarian carcinoma according to the International
Federation of Gynecology and Obstetrics (FIGO). They were
enrolled into the study from the University Hospital, Clinic of
Gynecological Surgery and Chair of Gynecologic Oncology
at Poznan University of Medical Sciences. Histopathological
classification, describing the stage, grade and tumor type, was
carried out by an experienced pathologist (Table 1). The
controls included 464 unrelated healthy female volunteers
who were matched by age to the cancer patients (Table 1).
The patients and healthy female volunteers were Caucasian
from the Wielkopolska area of Poland. Written informed
consent was obtained from all participating individuals. The
study design was accepted by the Local Ethical Committee of
Poznań University of Medical Sciences.
Genotyping
Genomic DNA was obtained from peripheral blood
leucocytes by salt extraction. DNA samples were genotyped
for the seven SNPs: intronic rs2072590 on 2q31 (HOXD-
AS1), intronic rs2665390 on 3q25 (TIPARP), rs10088218
and rs10098821 on 8q24, rs3814113 on 9p22, intronic
rs9303542 on 17q21 (SKAP1) and missense rs2363956 on
19p13 (Leu184Trp, ANKLE1) (Supplemental Table 1). SNPs
were selected based on the highest association in GWAS
studies [22–24]. Genotyping of the HOXD-AS1 rs2072590,
TIPARP rs2665390, 8q24 rs10088218 and rs10098821,
SKAP1 rs9303542 and ANKLE1 rs2363956 was performed
by high resolution melting curve analysis (HRM) on the
LightCycler 480 system (Roche Diagnostics, Mannheim,
Germany (Supplemental Table 2). Genotyping of the 9p22
rs3814113 SNP was performed by PCR, followed by appro-
priate restriction enzyme digestion (PCR-RFLP) according to
the manufacturer’s instructions (Fermentas, Vilnius, Lithua-
nia). Primer sequences and conditions for HRM and PCR-
RFLP analyses are presented in Supplemental Table 2.
Genotyping quality was assessed by commercial sequencing
of approximately 10 % randomly selected samples.
Statistical Analysis
Hardy-Weinberg equilibrium (HWE) was evaluated by
Pearson’s goodness-of-fit Chi-squared (χ2) statistic. The data
were tested for association with ovarian cancer using the
Cochran-Armitage trend test. The distinction in the allele
and genotype frequencies between cancer patients and healthy
female volunteers were determined using standard χ2 or Fish-
er tests. The odds ratio (OR) and associated 95 % confidence
intervals (95%CI) were also calculated. SNPs were assessed
under recessive and dominant inheritance models. To adjust
for the multiple testing, we used a Bonferroni correction. High
order gene-gene interactions among all tested polymorphic
loci were evaluated by the multifactor dimensionality reduc-
tion (MDR) approach (MDR version 2.0 beta 5) [25]. Based
on the obtained testing balanced accuracy and cross-validation
consistency values, the best statistical gene-gene interaction




Mean age±SD 53.9±9.1 52.8±8.2
Histological grade
G1 81 (29.7 %)
G2 101 (37.0 %)
G3 91 (33.3 %)
Gx 0 (0.0 %)
Clinical stage
I 104 (38.1 %)
II 43 (15.8 %)
III 91 (33.3 %)
IV 35 (12.8 %)
Histological type
Serous 97 (35.5 %)
Mucinous 30 (11.0 %)
Endometrioid 53 (19.4 %)
Clear cell 26 (9.5 %)
Brenne 0 (0.0 %)
Mixed 24 (8.8 %)
Solid 18 (6.6 %)
Untyped carcinoma 25 (9.2 %)



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































310 A. Mostowska et al.
models were established. A 1000-fold permutation test was
used to assess the statistical significance of MDR models
(MDR permutation testing module 0.4.9 alpha).
Results
Contribution of rs2072590 (HOXD-AS1), rs2665390
(TIPARP), rs10088218 and rs10098821 (8q24), rs3814113
(9p22), rs9303542 (SKAP1) and rs2363956 (ANKLE1) SNPs
to Ovarian Cancer Development
The prevalence of HOXD-AS1, TIPARP, 8q24, 9p22, SKAP1
and ANKLE1 genotypes did not display deviation from HWE
between the patient and control groups (p>0.05). The number
of genotypes, OR, and 95 % CI values for the seven HOXD-
AS1, TIPARP, 8q24, 9p22, SKAP1 and ANKLE1 polymor-
phisms are presented in Table 2. The lowest p values of the
trend test in patients with all histological EOT subtypes were
found for the 9p22 rs3814113 and 8q24 rs10098821 SNPs
(ptrend=0.010 and ptrend=0.014, respectively) (Table 2). More-
over, we observed significant p values of the trend for the
9p22 rs3814113 and 8q24 rs10098821SNPs for serous histo-
logical subtypes of ovarian cancer (ptrend=0.006 and ptrend=
0.033, respectively) (Table 2).
The statistical significance for multiple testing determined
by correction of gene number was p=0.007. Therefore, none
of the seven HOXD-AS1, TIPARP ,8q24, 9p22, SKAP1,and
ANKLE1 polymorphisms displayed a significant association
with all subtypes of ovarian cancer either in dominant or
recessive inheritance models (Table 2). Stratification of the
patients based on histological type of cancer revealed, in the
dominant hereditary model, a significant association of the
9p22 rs3814113 SNP with serous ovarian carcinoma, OR=
0.532 (95 % CI=0.342 - 0.827, p=0.005). However, the 9p22
rs3814113 polymorphism did not display significant associa-
tion with other histological types and any histological grade
and clinical stage. Furthermore, there was no significant asso-
ciation between the HOXD-AS, TIPARP, 8q24, SKAP1 and
ANKLE1 polymorphisms with clinical stage, histological
grade and subtype.
MDR Analysis of Gene-gene Interactions
among the rs2072590 (HOXD-AS1), rs2665390 (TIPARP),
rs10088218 and rs10098821 (8q24), rs3814113 (9p22),
rs9303542 (SKAP1) and rs2363956 (ANKLE1) SNPs
Exhaustive MDR analysis assessing two- to four-loci combi-
nations of all studied SNPs for each comparison did not reveal
statistical significance in predicting susceptibility to EOTs
development (Table 3). The best combination of possibly
interactive polymorphisms was observed for 8q24
rs10098821 and 9p22 rs3814113 (testing balanced accura-
cy=0.516 %, cross validation consistency of 3 out of 10,
permutation test p=0.682).
Discussion
Family and twin investigations have provided us with con-
crete evidence indicating that there are inherited genetic fac-
tors involved in susceptibility to the development of EOTs
[17, 18]. GWAS have been performed in order to identify
common low-penetrance ovarian cancer susceptibility genes
[22–24]. The GWAS conducted by Song et al. (2009) dem-
onstrated the 9p22 rs3814113 SNP to be a significant genetic
risk factor contributing to all histological subtypes of EOTs
[22]. In addition to this finding, GWAS analysis performed by
Goode et al. (2010) found genome-wide significant associa-
tion for the 3q25 rs2665390, 17q21 rs9303542, 8q24
rs10088218 and 2q31 rs2072590 SNPs with all EOTs sub-
types [23]. The GWAS by Bolton et al. (2010) demonstrated
that SNPs rs8170 and rs2363956 on 19p13 displayed genome-
wide significance for susceptibility of serous ovarian cancer
but not all histological subtypes of EOTs [24].
Our follow-up studies, conducted in Caucasian women
with ovarian cancer enrolled in the Wielkopolska area of
Poland, identify a significant p trend of rs3814113 on 9p22
with all sybtypes of EOTs. In addition to this finding, we
observed that rs3814113 on 9p22 may play a protective role
from the development of serous histological subtypes of ovar-
ian carcinoma. The stratification of the GWAS by Song et al.
(2009) that was based on histological subtypes also indicated
that rs3814113 exhibited the greatest association with serous
Table 3 Results of gene-gene
interactions analyzed by MDR
method
a Significance of accuracy (em-







8q24_rs10098821, 9p22_rs3814113 0.516 60 % 0.682
8q24_rs10098821, 9p22_rs3814113, 17q21_rs9303542 0.514 40 % 0.708
2q31_rs2072590, 9p22_rs3814113, 17q12_rs757210,
19p13_rs2363956
0.507 70 % 0.783
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subtypes of EOTs [22]. Moreover, the 9p22 rs3814113 SNP
has been demonstrated to be a protective genetic factor of
ovarian cancer for carriers of BRCA1 or BRCA2 mutations
[26]. There has also been a recent evaluation of the functional
role of seven ovarian cancer susceptibility GWAS polymor-
phisms in association with microRNAs (miRNAs) presence
[27]. This study demonstrated the highest numbers of
miRNAs, 68 significantly linked to the rs3814113 SNP [27].
Moreover, the rs3814113 polymorphism was significantly
associated with miR-17–92 cluster, which is considered the
most remarkable cluster involved in tumorigenesis [27]. Ad-
ditionally, cell carriers of the rs3814113 SNP displayed prom-
inence of several elementary biological pathways such as
cellular response to stress, adenyl nucleotide binding, intra-
cellular organelle lumen, and others [27]. Other functional
studies assessed the relationship between changeability of
gene expression and the presence of seven ovarian cancer
susceptibility GWAS SNPs [28]. These studies demonstrated
significant association between the 9p22 rs3814113 SNP and
changes in the levels of 274 mRNAs [28]. However, the
strongest association of the rs3814113 SNP was observed
for increased levels of MT1G and ATL2 mRNAs, which
respectively encode metallothionein 1G (OMIM *156353)
and atlastin GTPase (OMIM *609368) [28].
Our studies also found significant p trend values for the
8q24 rs10098821 SNP for all patients with ovarian cancer,
and also specifically for serous histological subtype. The
Goode et al. (2010) GWAS analysis also demonstrated a
generally greater association of the 8q24 rs10098821 SNPs
with serous as compared to other ovarian EOTs subtypes [23].
Moreover, the 8q24 locus was found to be a risk for several
malignancies encompassing breast, prostate, and colorectal
cancer [29, 30]. A functional association study between
GWAS SNPs and whole genome mRNA expression profiles
revealed that the 8q24 rs10098821 SNP had the largest num-
ber of significant associations, specifically 38 [28]. The study
also indicated possible cis-associations between rs10098821
andMYC expression [28]. The 8q24 polymorphisms linked to
EOTs and other carcinomas are situated approximately 700 kb
3′ of the MYC protooncogene, and these SNPs probably
control the expression of this oncogene distally [28, 31].
Presently, genetic risk evaluation for ovarian cancer can be
conducted for subjects with a family history of some cancer
and/or BRCA1/2 mutations identified within families. How-
ever, the usage of low-penetrance SNPs in screening for the
risk of ovarian cancer in various ethnicities has not yet been
employed. This is in contrast to colorectal and breast cancers,
where combinations of low penetrance risk genetic variants
are already employed for susceptibility screening in some
populations [32, 33].
It was demonstrated that the 9p22 rs3814113 and 8q24
rs10098821 variants were associated with the risk of EOTs
in subjects of European ancestry [22, 23]. In the subjects of
non-European ancestry (African or Asian ethnic group), these
SNPs did not show statistically significant correlations with the
risk of EOTs; however, these results could be due to small sample
size [22]. Our study found a significant association of the 9p22
rs3814113 SNP with serous subtypes, and significant trend p-
values for the 9p22 rs3814113 and 8q24 rs10098821 SNPs with
all EOTs and serous subtypes in Caucasian patients from the
Wielkopolska region of Poland. However, our replication studies
have been conducted in relatively small patient and control groups,
resulting in a possible missed significant association for the other
studied SNPs in ovarian cancer. Therefore, this study should be
replicated in other independent cohorts to validate the role of low
penetrance SNPs in EOTs development and also in their use as
screening tools in the evaluation of ovarian cancer susceptibility.
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